StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — Pradip Hotchandani, Prudent Corporate Advisory Services

BUYEmcure Pharmaceuticals Limited
Emcure Pharmaceuticals share price target & all analyst calls

byPradip Hotchandani, Prudent Corporate Advisory ServicesHorizon: NA (inferred Swing (≤2wk))20 Jul 2026via CNBC Awaaz.

Entry₹1,840Inferred
Target₹1,930
Total upside +4.89% (call closed)
Stop loss₹1,790-2.72% risk
Exit₹1,93021 Jul 2026, 3:25 pm
Target hit+4.89%0.00%upside left
Follow Pradip Hotchandani for new calls(20% target hit, 46 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 209 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 21 Jul 2026
6 supporting1 opposing
Supports the BUY call (6)

Emcure Pharmaceuticals has received CDSCO approval to expand the use of its drug Poviztra for MASH indication, potentially increasing market reach and revenue.

BSE · Company Update·20 Jul · today

(opens in new tab)

Novo Nordisk's Wegovy wins India nod for fatty liver disease; Emcure to distribute

NewsCnbc-Tv18·17 Jul · 4d ago

(opens in new tab)

Emcure Pharmaceuticals Ltd's press release indicates consolidation of Gennova ownership and a sharpened focus on biologics, with Samit Mehta leading growth.

BSE · Company Update·13 Jul · 1w ago

(opens in new tab)

Emcure Pharmaceuticals Limited is acquiring an additional 12.05% stake in its subsidiary, Gennova Biopharmaceuticals Limited, for Rs. 2,318.7 Million. This acquisition will make Gennova a wholly-owned

NSE · Acquisition·13 Jul · 1w ago

(opens in new tab)

Emcure Pharmaceuticals Ltd has executed Share Transfer Agreements to acquire an additional 12.05% stake in Gennova Biopharmaceuticals Ltd, making Gennova a wholly-owned subsidiary upon completion. The

BSE · Company Update·13 Jul · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

Emcure Pharmaceuticals gets CDSCO nod for MASH treatment in adults with liver fibrosis

NewsCnbc-Tv18·20 Jul · today

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Emcure Pharmaceuticals

All analyst calls on Emcure Pharmaceuticals

More from Pradip Hotchandani, Prudent Corporate Advisory Services

Every call and its outcome